PAF1: A Potential Drug Target and Biomarker (G54623)

Target Name: PAF1

NCBI ID: G54623

PAF1

PAF1: A Potential Drug Target and Biomarker

Parathyroid hormone-related protein 1 (PAF1) is a protein that is expressed in most parathyroid glands and is involved in the regulation of calcium homeostasis. It has been identified as a potential drug target and biomarker for various diseases, including osteoporosis, bone fractures, and chronic pain.

The parathyroid gland is a small gland located in the neck that produces parathyroid hormone (PTH). PTH is essential for maintaining calcium homeostasis and plays a crucial role in regulating the activity of several enzymes that are involved in bone resorption and formation. The loss of parathyroid tissue due to surgery or other conditions can lead to an imbalance in PTH levels and contribute to the development of various diseases.

PAF1 is a 19-kDa protein that is expressed in most parathyroid glands. It is composed of a unique transmembrane domain, a cytoplasmic tail, and a unique N-terminus. The transmembrane domain is responsible for the protein's stability and cytoplasmic tail is involved in its stability and interaction with other proteins. The unique N-terminus is involved in the protein's interaction with PTH and is critical for its stability.

PAF1 is involved in several physiological processes that are essential for human health, including bone development and maintenance, calcium homeostasis, and pain perception. It is a key regulator of the activity of enzymes that are involved in bone resorption and formation, including the activity of osteoclasts, which are cells that break down bone tissue, and the activity of osteoblast, which is a cell that rebuilds bone tissue.

PAF1 is also involved in the regulation of calcium homeostasis, which is critical for many physiological processes in the body, including muscle contractions, nerve function, and blood clotting. It is a key regulator of the activity of enzymes that are involved in the regulation of calcium levels in the cytosol, including the enzyme calbindin.

In addition to its role in calcium homeostasis, PAF1 is also involved in the regulation of pain perception. It is a key regulator of the activity of pain modulators, including opioids, which are involved in the relief of pain. The loss of PAF1 has been linked to the development of chronic pain, including osteoporosis, which is a condition that is characterized by the loss of bone tissue due to aging or other conditions.

PAF1 is also a potential biomarker for several diseases, including osteoporosis, bone fractures, and chronic pain. The loss of parathyroid tissue due to surgery or other conditions can lead to an imbalance in PTH levels, which can contribute to the development of osteoporosis. In addition, the decreased activity of PAF1 due to aging can be an indicator of the development of chronic pain.

In conclusion, PAF1 is a protein that is expressed in most parathyroid glands and is involved in the regulation of several physiological processes that are essential for human health. It is a potential drug target and biomarker for various diseases, including osteoporosis, bone fractures, and chronic pain. Further research is needed to fully understand the role of PAF1 in these diseases and to develop effective treatments.

Protein Name: PAF1 Homolog, Paf1/RNA Polymerase II Complex Component

Functions: Component of the PAF1 complex (PAF1C) which has multiple functions during transcription by RNA polymerase II and is implicated in regulation of development and maintenance of embryonic stem cell pluripotency. PAF1C associates with RNA polymerase II through interaction with POLR2A CTD non-phosphorylated and 'Ser-2'- and 'Ser-5'-phosphorylated forms and is involved in transcriptional elongation, acting both independently and synergistically with TCEA1 and in cooperation with the DSIF complex and HTATSF1. PAF1C is required for transcription of Hox and Wnt target genes. PAF1C is involved in hematopoiesis and stimulates transcriptional activity of KMT2A/MLL1; it promotes leukemogenesis through association with KMT2A/MLL1-rearranged oncoproteins, such as KMT2A/MLL1-MLLT3/AF9 and KMT2A/MLL1-MLLT1/ENL. PAF1C is involved in histone modifications such as ubiquitination of histone H2B and methylation on histone H3 'Lys-4' (H3K4me3). PAF1C recruits the RNF20/40 E3 ubiquitin-protein ligase complex and the E2 enzyme UBE2A or UBE2B to chromatin which mediate monoubiquitination of 'Lys-120' of histone H2B (H2BK120ub1); UB2A/B-mediated H2B ubiquitination is proposed to be coupled to transcription. PAF1C is involved in mRNA 3' end formation probably through association with cleavage and poly(A) factors. In case of infection by influenza A strain H3N2, PAF1C associates with viral NS1 protein, thereby regulating gene transcription. Connects PAF1C with the RNF20/40 E3 ubiquitin-protein ligase complex. Involved in polyadenylation of mRNA precursors. Has oncogenic activity in vivo and in vitro

The "PAF1 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about PAF1 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets